Register with MSD Connect
✔ Sign up for events
✔ Complete learning modules
✔ Receive cancer resources
✔ Access additional content
KEYNOTE-407 data presentation: KEYTRUDA® (pembrolizumab), in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of metastatic squamous NSCLC
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
PDF, 3.60 MB
Download our KEYNOTE-407 slide deck that discusses KEYTRUDA (pembrolizumab) plus carboplatin-paclitaxel/nab-paclitaxel for the first-line treatment of metastatic squamous NSCLC.
Find out more information about KEYTRUDA in metastatic NSCLC:
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website.
